A UK-based SME has developed intrinsically fluorescent derivatives of retinoid cell signalling molecules. Having developed these compounds for cell imaging the company is looking at other applications including diagnostic testing. The SME is looking to partner with companies and research organisations experienced in developing diagnostic tests and / or devices to explore this application further. Partnerships are envisaged as joint ventures, research cooperations or technical cooperations.
Cell signalling molecules are involved in a wide variety of cell processes making them and their signalling pathways of interest for the diagnosis of diseases arising from changes in cell processes such as cancer. Retinoids are an important group of such cell signalling molecules.
A UK-based SME has developed a library of retinoid derivatives that exhibit strong intrinsic fluorescence, whilst retaining the biological activity of the original molecule. The company has had success in developing and using these compounds for cell imaging applications and is now looking at other potential uses of the technology. They are interested in exploring the potential of these compounds as an indicator agent in diagnostic medical devices with the focus on conditions associated with changes in cell processes regulated by retinoids, particularly proliferation, differentiation and apoptosis making cancer an obvious first choice target.
The SME is looking for companies or research organisation active in the development of new diagnostic tests and especially diagnostic devices to provide expertise for exploring the potential of the SME's fluorescent retinoid derivatives as an active or reporter agent in diagnostic tests. It is envisaged that the partnership will take the form of a joint venture agreement, research cooperation agreement or a technical cooperation agreement.
- Type of partner sought: Expertise in developing diagnostic tests and in particular the incorporation of these tests into diagnostic devices.
Experience of working with novel compounds and developing for different applications.
Knowledge of the medical and diagnostic devices regulatory requirements in different geographies and what is required for registration of a new test.
- Specific area of activity of the partner: The UK SME is looking to partner with companies and research organisations that are working on the development of new diagnostic tests particularly in the field of cancer. Partners with experience of developing tests for diagnostic devices or devices themselves are particularly sought.
The UK SME will provide its library of fluorescent retinoid derivatives as well as its expertise on developing these derivatives in order to optimise and potentially develop new compounds for diagnostic tests. The company will work with a partner to explore the potential for the SME's fluorescent retinoid derivatives to be used as the basis for diagnostic tests. It is envisaged that the partnership will take the form of a joint venture agreement, a research cooperation agreement or a technical cooperation agreement.
29/05/2018 - Trading Internationally - Lochaber WEBINAR
29/05/2018 - Trading Internationally - Caithness WEBINAR